242 related articles for article (PubMed ID: 10623433)
41. Serum concentration of transforming growth factor (TGF)-beta 1 does not predict advanced liver fibrosis in children with chronic hepatitis B.
Lebensztejn DM; Sobaniec-Lotowska M; Kaczmarski M; Werpachowska I; Sienkiewicz J
Hepatogastroenterology; 2004; 51(55):229-33. PubMed ID: 15011870
[TBL] [Abstract][Full Text] [Related]
42. [Dynamic monitoring of sIL-2R, IL-2 and IL-6 levels of serum after double-hand transplantation].
Xiang D; Pei G; Qiu Y
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2004 May; 18(3):232-5. PubMed ID: 15211844
[TBL] [Abstract][Full Text] [Related]
43. Serum levels of IL-18 and sIL-2R in patients with alopecia areata receiving combined therapy with oral cyclosporine and steroids.
Lee D; Hong SK; Park SW; Hur DY; Shon JH; Shin JG; Hwang SW; Sung HS
Exp Dermatol; 2010 Feb; 19(2):145-7. PubMed ID: 19758343
[TBL] [Abstract][Full Text] [Related]
44. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
[TBL] [Abstract][Full Text] [Related]
45. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.
Nassonov EL; Samsonov MY; Tilz GP; Beketova TV; Semenkova EN; Baranov A; Wachter H; Fuchs D
J Rheumatol; 1997 Apr; 24(4):666-70. PubMed ID: 9101499
[TBL] [Abstract][Full Text] [Related]
46. Cellular immune response and cytokine profile among hepatitis C positive living donor renal transplant recipients.
Justa S; Minz RW; Minz M; Sharma A; Pasricha N; Anand S; Chawla YK; Sakhuja VK
Transplantation; 2010 Sep; 90(6):654-60. PubMed ID: 20622752
[TBL] [Abstract][Full Text] [Related]
47. Lack of increased serum interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human interferon alpha therapy.
Minelli R; Girasole G; Pedrazzoni M; Giuliani N; Schianchi C; Giuberti T; Braverman LE; Salvi M; Roti E
J Investig Med; 1996 Aug; 44(6):370-4. PubMed ID: 8795300
[TBL] [Abstract][Full Text] [Related]
48. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature.
Kötter I; Koch S; Vonthein R; Rückwaldt U; Amberger M; Günaydin I; Zierhut M; Stübiger N
Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S20-6. PubMed ID: 16273760
[TBL] [Abstract][Full Text] [Related]
49. Serial monitoring of soluble interleukin-2 receptor as a rapid marker of cytomegalovirus infection and response to antiviral therapy.
Rossi S; Schroeder T; Muth K; Hanto D; Munda R; Hariharan S; First MR; Ryckman F; Balistreri W
Clin Transplant; 1996 Feb; 10(1 Pt 1):45-50. PubMed ID: 8652897
[TBL] [Abstract][Full Text] [Related]
50. Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus.
Hayashi J; Kishihara Y; Yamaji K; Yoshimura E; Ohmiya M; Tani Y; Ikematsu H; Kashiwagi S
Dig Dis Sci; 1995 Aug; 40(8):1837-41. PubMed ID: 7648988
[TBL] [Abstract][Full Text] [Related]
51. Serum levels of soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alpha.
Morishima I; Kumada T; Nakano S; Takeda I; Sugiyama K; Osada T; Kiriyama S; Ohki H; Suga T; Ito O
Scand J Gastroenterol; 1995 Aug; 30(8):807-11. PubMed ID: 7481551
[TBL] [Abstract][Full Text] [Related]
52. Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases.
Yamaguchi S; Onji M; Ohta Y
Hepatogastroenterology; 1988 Oct; 35(5):245-8. PubMed ID: 3068111
[TBL] [Abstract][Full Text] [Related]
53. Neopterin serum levels in pancreatic adenocarcinoma.
Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
[TBL] [Abstract][Full Text] [Related]
54. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
Gottschlich S; Görögh T; Lippert BM; Niemann AM; Folz BJ; Werner JA
Anticancer Res; 1997; 17(4B):2921-2. PubMed ID: 9329564
[TBL] [Abstract][Full Text] [Related]
55. Soluble interleukin-2 receptor and interleukin-4 in sera of asthmatic children before and after a prednisolone course.
Tang RB; Chen SJ
Ann Allergy Asthma Immunol; 2001 Mar; 86(3):314-7. PubMed ID: 11289331
[TBL] [Abstract][Full Text] [Related]
56. [The clinical significance of the measurement of serum soluble interleukin-2 receptors in various diseases].
Sugimoto H; Hashimoto N; Suzuki S; Gejyo F
Rinsho Byori; 1996 Feb; 44(2):176-82. PubMed ID: 8851203
[TBL] [Abstract][Full Text] [Related]
57. The effects of interferon-alpha on serum lipid peroxidation and total thiol content in patients with chronic active hepatitis-C.
Mutlu-Türkoglu U; Ademoglu E; Türkoglu S; Badur S; Uysal M; Toker G
Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):357-61. PubMed ID: 9261895
[TBL] [Abstract][Full Text] [Related]
58. Melatonin as a new possible anti-inflammatory agent.
Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
[TBL] [Abstract][Full Text] [Related]
59. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
[TBL] [Abstract][Full Text] [Related]
60. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis.
Barak V; Selmi C; Schlesinger M; Blank M; Agmon-Levin N; Kalickman I; Gershwin ME; Shoenfeld Y
J Autoimmun; 2009; 33(3-4):178-82. PubMed ID: 19846277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
